KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Common Equity: 2009-2014

Historic Common Equity for Biocryst Pharmaceuticals (BCRX) over the last 6 years, with Dec 2014 value amounting to $75.6 million.

  • Biocryst Pharmaceuticals' Common Equity fell 23.26% to $64.0 million in Q3 2015 from the same period last year, while for Sep 2015 it was $64.0 million, marking a year-over-year decrease of 23.26%. This contributed to the annual value of $75.6 million for FY2014, which is 6817.14% up from last year.
  • According to the latest figures from FY2014, Biocryst Pharmaceuticals' Common Equity is $75.6 million, which was up 6,817.14% from -$1.1 million recorded in FY2013.
  • Biocryst Pharmaceuticals' Common Equity's 5-year high stood at $75.6 million during FY2014, with a 5-year trough of -$1.1 million in FY2013.
  • For the 3-year period, Biocryst Pharmaceuticals' Common Equity averaged around $24.7 million, with its median value being -$454,000 (2012).
  • Its Common Equity has fluctuated over the past 5 years, first tumbled by 148.02% in 2013, then skyrocketed by 6,817.14% in 2014.
  • Biocryst Pharmaceuticals' Common Equity (Yearly) stood at $65.5 million in 2010, then plummeted by 77.40% to $14.8 million in 2011, then plummeted by 103.07% to -$454,000 in 2012, then crashed by 148.02% to -$1.1 million in 2013, then skyrocketed by 6,817.14% to $75.6 million in 2014.